H19 expression in hepatic metastases from a range of human carcinomas. Issue 10 (27th September 2005)

• Record Type: Journal Article
• Authors: Fellig, Y; Ariel, I; Ohana, P; Schachter, P; Sinelnikov, I; Birman, T; Ayesh, S; Schneider, T; de Groot, N; Czerniak, A; Hochberg, A
• Is Part Of: Journal of clinical pathology. Volume 58:Issue 10(2005)
• Page Start: 1064
• Page End: 1068
• Publication Date: 2005-09-27
• Subjects: CI, confidence interval -- IGF, insulin-like growth factor; H19 gene -- hepatic metastases (from carcinomas) -- in situ hybridisation -- DNA based therapy -- prognostic value; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jcp.2004.023648
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Aims: To investigate the expression of the imprinted oncofetal H19 gene in hepatic metastases derived from a range of human carcinomas and assess its prognostic value with the view of developing a DNA based treatment for such metastases. Methods: Non-radioactive in situ hybridisation for H19 RNA was performed on paraffin wax embedded sections of liver biopsies or partial hepatectomy specimens, taken from 80 patients with hepatic metastases derived from carcinomas from several medical centres in Israel. The degree of expression was graded qualitatively according to the number of cells expressing H19 and the intensity of staining. The medical files were searched for demographic data and survival times before and after diagnosis of hepatic metastases. Results: H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. Conclusions: H19 is highly expressed in more than half of hepatic metastases derived from a range of carcinomas. Thus, these metastases may be suitable candidates for H19 DNA based treatment. Further studies are needed to determine whether H19 expression has prognostic value in metastatic liver disease using larger numbers of specific subtypes of primary carcinomas.